Marina Biotech makes organisational changes

23-Sep-2011

Creates the position of executive vice president of r&d

Marina Biotech, a US nucleic acid-based drug discovery and development firm, has made some organisational changes.

Richard Ho has joined the firm in the newly created position of executive vice president, Research and Development.

In addition, Philip Ranker has become interim chief financial officer, replacing Peter Garcia who has resigned from the role to pursue other opportunities.

Barry Polisky has moved from chief scientific officer to distinguished scientist and has become chairman of the firm's Scientific Advisory Panel and Michael Templin has been promoted to the newly created position of senior vice president and chief technology officer.

Finally, Alan Dunton has joined the firm as consulting chief medical officer.

Marina Biotech’s goal is to improve human health through the development of RNAi and RNA-based compounds and drug delivery technologies.

Companies